242 related articles for article (PubMed ID: 23563754)
21. Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles.
Yang H; Lin S; Cui J
Gene; 2014 Feb; 535(2):312-7. PubMed ID: 24262935
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Xiao G; Tang X; Yao C; Wang C
Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Noh EK; Kim H; Park MJ; Baek JH; Park JH; Cha SJ; Won JH; Min YJ
Leuk Res; 2010 Nov; 34(11):1501-5. PubMed ID: 20226526
[TBL] [Abstract][Full Text] [Related]
24. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Lam HK; Li K; Chik KW; Yang M; Liu VC; Li CK; Fok TF; Ng PC; Shing MM; Chuen CK; Yuen PM
Int J Oncol; 2005 Aug; 27(2):537-45. PubMed ID: 16010437
[TBL] [Abstract][Full Text] [Related]
26. Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
Bhattacharjee H; Carbrey J; Rosen BP; Mukhopadhyay R
Biochem Biophys Res Commun; 2004 Sep; 322(3):836-41. PubMed ID: 15336539
[TBL] [Abstract][Full Text] [Related]
27. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Zheng PZ; Wang KK; Zhang QY; Huang QH; Du YZ; Zhang QH; Xiao DK; Shen SH; Imbeaud S; Eveno E; Zhao CJ; Chen YL; Fan HY; Waxman S; Auffray C; Jin G; Chen SJ; Chen Z; Zhang J
Proc Natl Acad Sci U S A; 2005 May; 102(21):7653-8. PubMed ID: 15894607
[TBL] [Abstract][Full Text] [Related]
28. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
[TBL] [Abstract][Full Text] [Related]
29. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
30. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
31. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
[TBL] [Abstract][Full Text] [Related]
32. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
Zuo L; Li J; Yang Y; Wang X; Shen T; Xu CM; Zhang ZN
Ann Hematol; 2004 Dec; 83(12):751-8. PubMed ID: 15480664
[TBL] [Abstract][Full Text] [Related]
33. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
34. Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
Giri U; Terry NH; Kala SV; Lieberman MW; Story MD
Cancer Chemother Pharmacol; 2005 Jun; 55(6):511-21. PubMed ID: 15761769
[TBL] [Abstract][Full Text] [Related]
35. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
[TBL] [Abstract][Full Text] [Related]
36. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
38. Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.
Mozdarani H; Asghari F
Arch Iran Med; 2010 Jan; 13(1):26-33. PubMed ID: 20039766
[TBL] [Abstract][Full Text] [Related]
39. [The expression of AQP9 in HepG2 cells affects cell biological behaviors and sensitivity to As2O3].
Tang J; Wang C; Jiang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):769-74. PubMed ID: 26062419
[TBL] [Abstract][Full Text] [Related]
40. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Davison K; Côté S; Mader S; Miller WH
Leukemia; 2003 May; 17(5):931-40. PubMed ID: 12750708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
